Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure

Journal of Diabetes and its Complications

Volumn 31, Issue 7, 2017, Pages 1215-1221

  Kosiborod, Mikhail ^a   Gause Nilsson, Ingrid ^b   Xu, John ^c   Sonesson, Christian ^b   Johnsson, Eva ^b  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Cardiovascular safety; Dapagliflozin; Efficacy; Heart failure; Pooled analysis; Type 2 diabetes mellitus

Indexed keywords

CREATININE; DAPAGLIFLOZIN; HEMOGLOBIN A1C; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; OSMOTIC DIURETIC AGENT; SODIUM GLUCOSE COTRANSPORTER;

ADULT; ANURIA; ARTICLE; BEHAVIOR DISORDER; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; CREATININE CLEARANCE; DEHYDRATION; DIABETIC PATIENT; DISEASE DURATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; GENITAL TRACT INFECTION; HAZARD RATIO; HEART FAILURE; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; HYPOTENSION; KIDNEY FAILURE; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UNSTABLE ANGINA PECTORIS; URINARY TRACT INFECTION; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DIABETIC CARDIOMYOPATHY; HYPERGLYCEMIA; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; RISK FACTOR; SECONDARY PREVENTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DIURETICS, OSMOTIC; FEMALE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HEART FAILURE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; MEMBRANE TRANSPORT MODULATORS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SECONDARY PREVENTION; SODIUM-GLUCOSE TRANSPORT PROTEINS;

EID: 85015628980     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2017.02.001     Document Type: Article

References (46)

1. McGuire, D.K., Gore, M.O., Masoudi, F.A., Diabetes and heart failure in patients with coronary disease: separating markers from mediators. Diabetes Care 33 (2010), 2120–2122.
2. Kosiborod, M., Inzucchi, S.E., Spertus, J.A., Wang, Y., Masoudi, F.A., Havranek, E.P., et al. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. Circulation 119 (2009), 1899–1907.
3. van Deursen, V.M., Urso, R., Laroche, C., Damman, K., Dahlstrom, U., Tavazzi, L., et al. Co-morbidities in patients with heart failure: an analysis of the European heart failure pilot survey. Eur J Heart Fail 16 (2014), 103–111.
4. Held, C., Gerstein, H.C., Yusuf, S., Zhao, F., Hilbrich, L., Anderson, C., et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 115 (2007), 1371–1375.
5. van Melle, J.P., Bot, M., de Jonge, P., de Boer, R.A., van Veldhuisen, D.J., Whooley, M.A., Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care 33 (2010), 2084–2089.
6. Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–322.
7. Roger, V.L., Epidemiology of heart failure. Circ Res 113 (2013), 646–659.
8. Heidenreich, P.A., Albert, N.M., Allen, L.A., Bluemke, D.A., Butler, J., Fonarow, G.C., et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6 (2013), 606–619.
9. Shindler, D.M., Kostis, J.B., Yusuf, S., Quinones, M.A., Pitt, B., Stewart, D., et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol 77 (1996), 1017–1020.
10. Eurich, D.T., Majumdar, S.R., McAlister, F.A., Tsuyuki, R.T., Johnson, J.A., Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28 (2005), 2345–2351.
11. Gilbert, R.E., Krum, H., Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 385 (2015), 2107–2117.
12. Bailey, C.J., Gross, J.L., Pieters, A., Bastien, A., List, J.F., Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375 (2010), 2223–2233.
13. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
14. ® trial. Eur Heart J 37 (2016), 1526–1534.
15. Weber, M.A., Mansfield, T.A., List, J.F., Ptaszynska, A., Dapagliflozin lowered ambulatory blood pressure in patients with T2DM and hypertension inadequately controlled by a renin–angiotensin system blocker with or without another agent. Diabetes, 63, 2014, A266.
16. Cefalu, W.T., Leiter, L.A., de Bruin, T.W., Gause-Nilsson, I., Sugg, J., Parikh, S.J., Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care 38 (2015), 1218–1227.
17. Kohan, D.E., Fioretto, P., Tang, W., List, J.F., Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85 (2014), 962–971.
18. Leiter, L.A., Cefalu, W.T., de Bruin, T.W., Gause-Nilsson, I., Sugg, J., Parikh, S.J., Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc 62 (2014), 1252–1262.
19. Strojek, K., Yoon, K.H., Hruba, V., Elze, M., Langkilde, A.M., Parikh, S., Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13 (2011), 928–938.
20. Wilding, J.P., Woo, V., Soler, N.G., Pahor, A., Sugg, J., Rohwedder, K., et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 156 (2012), 405–415.
21. Langkilde, A.M., Johansson, P., Ptaszynska, A., Johnsson, E., Cardiovascular safety of the SGLT2 inhibitor dapagliflozin: meta-analysis with > 6000 patient-years exposure. Circulation, 128, 2013, A11105.
22. Haas, B., Eckstein, N., Pfeifer, V., Mayer, P., Hass, M.D., Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutr Diabetes, 4, 2014, e143.
23. Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U.C., et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38 (2015), 420–428.
24. Sonesson, C., Frederich, R., Johansson, P., Gause-Nilsson, I., Langkilde, A.M., List, J.F., Cardiovascular safety of dapagliflozin in type 2 diabetes mellitus (T2DM) patients with various degrees of cardiovascular risk. Eur Heart J, 35(Suppl. 1), 2014, 1072.
25. Sonesson, C., Johansson, P.A., Johnsson, E., Gause-Nilsson, I., Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol, 15, 2016, 37.
26. Ghali, J.K., Tam, S.W., The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. J Card Fail 16 (2010), 419–431.
27. Cefalu, W.T., Leiter, L., Johnsson, E., Sugg, J., Gause-Nilsson, I., Safety and efficacy of dapagliflozin in patients with T2DM and cardiovascular disease receiving loop diuretics. Diabetes, 64, 2015, A314 [1216-P].
28. Udell, J.A., Cavender, M.A., Bhatt, D.L., Chatterjee, S., Farkouh, M.E., Scirica, B.M., Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 3 (2015), 356–366.
29. Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
30. Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
31. Scirica, B.M., Braunwald, E., Raz, I., Cavender, M.A., Morrow, D.A., Jarolim, P., et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130 (2014), 1579–1588.
32. White, W.B., Cannon, C.P., Heller, S.R., Nissen, S.E., Bergenstal, R.M., Bakris, G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
33. Zannad, F., Cannon, C.P., Cushman, W.C., Bakris, G.L., Menon, V., Perez, A.T., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
34. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
35. Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R.S., Nielsen, R., Hanselmann, A., et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19 (2016), 69–77.
36. Margulies, K.B., Anstrom, K.J., Redfield, M.M., Givertz, M.M., Oliveira, G.H., Cole, R., et al. A randomized trial of liraglutide for high-risk heart failure patients with reduced ejection fraction (FIGHT). Circulation, 132, 2015, 2268 [Abstract 20102].
37. Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Kober, L.V., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
38. Gerstein, H.C., Miller, M.E., Genuth, S., Ismail-Beigi, F., Buse, J.B., Goff, D.C. Jr., et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364 (2011), 818–828.
39. Chaudhry, S.I., Wang, Y., Concato, J., Gill, T.M., Krumholz, H.M., Patterns of weight change preceding hospitalization for heart failure. Circulation 116 (2007), 1549–1554.
40. Frier, B.M., Schernthaner, G., Heller, S.R., Hypoglycemia and cardiovascular risks. Diabetes Care 34 (2011), S132–S137.
41. Abdul-Ghani, M.A., Norton, L., DeFronzo, R.A., Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep 12 (2012), 230–238.
42. AstraZeneca, Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). https://clinicaltrials.gov/ct2/show/NCT01730534?term=declare+timi+58&rank=1, 2012 [accessed 4 January 2017].
43. Saint Luke's Health System, Dapagliflozin effect on symptoms and biomarkers in diabetes patients with heart failure (DEFINE-HF). https://clinicaltrials.gov/ct2/show/NCT02653482?term=nct02653482&rank=1, 2016 [accessed 4 January 2017].
44. Tanaka, A., Inoue, T., Kitakaze, M., Oyama, J., Sata, M., Taguchi, I., et al. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. Cardiovasc Diabetol, 15, 2016, 57.
45. AstraZeneca, AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure. https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2016/astrazeneca-announces-two-new-phase-IIIb-trials-for-Forxiga-in-chronic-kidney-disease-and-chronic-heart-failure-120920161.html, 2016 [accessed 4 January 2017].
46. ® (empagliflozin) to be studied for the treatment of people with chronic heart failure. https://www.boehringer-ingelheim.com/press-release/jardiance-empagliflozin-be-studied-treatment-people-chronic-heart-failure, 2016 [accessed 30 December 2016].